Editorial
The Advanced Practitioner’s Role in Treating Older Adults With Hematologic Malignancies
Sandra E. Kurtin, PhD, ANP-C, AOCN®
Read MoreMeeting Abstract
ASH Highlights and Commentary: Chronic Lymphocytic Leukemia
Read MoreMeeting Abstract
ASH Highlights and Commentary: Acute Myeloid Leukemia and Myelodysplastic Syndromes
Read MoreMeeting Abstract
ASH Highlights and Commentary: Multiple Myeloma
Read MoreEditorial
Acute Myeloid Leukemia: An Ever-Changing Disease
Nancy M. Nix, PharmD, BCPS, BCOP, and Allyson Price, MPAS, PA-CRead MoreReview Article
Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia
Nancy M. Nix, PharmD, BCPS, BCOP, and Allyson Price, MPAS, PA-CRead MoreReview Article
The Role of the Advanced Practitioner in Enhancing Outcomes
Nancy M. Nix, PharmD, BCPS, BCOP, and Allyson Price, MPAS, PA-CRead MoreAppendix
Appendix: Key Information on Newly Approved AML Drugs
Nancy M. Nix, PharmD, BCPS, BCOP, and Allyson Price, MPAS, PA-CRead MoreEditorial
CAR T-Cell Therapy for Large B-Cell Lymphoma
Maritza C. Alencar, DNP, MBA, APRN-BC, BMTCN®Read MoreReview Article
Anti-CD19 CAR T-Cell Therapy for Adult Patients With Refractory Large B-Cell Lymphoma
Kathleen McDermott, RN, BSN, OCN®, BMTCN®, and Lauren Spendley, AGNP, MSN, AOCN®Read MoreReview Article
CAR T-Cell Therapy: Adverse Events and Management
Sherry Adkins, RN, MSN, ANP-CRead MoreReview Article
Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy
Alix Beaupierre, RN, BSN, OCN®, Nicole Kahle, MS, RN, OCN®, BMTCN®, Rachel Lundberg, PA-C, MPAS, and Amy Patterson, MSN, APRN, AOCNS®, BMTCN®Read MoreEditorial
A Letter From the Guest Editor
Sandra E. Kurtin, PhD, ANP-C, AOCN®Read MoreCommentary
ASH Highlights and Commentary: Multiple Myeloma
Josh Epworth, ARNPRead MoreCommentary
ASH Highlights and Commentary: Acute Myeloid Leukemia
Lindsey Lyle, MS, PA-CRead MoreCommentary
ASH Highlights and Commentary: Leukemias and Lymphomas
Sandra E. Kurtin, PhD, ANP-C, AOCN®Read MoreEditorial
Immuno-Oncology Essentials: An Overview
Brianna Hoffner, MSN, ANP-BC, AOCNP®Read MoreReview Article
Meeting the Challenge of Immune-Related Adverse Events With Optimized Telephone Triage and Dedicated Oncology Acute Care
Brianna Hoffner, MSN, ANP-BC, AOCNP®, and Krista M. Rubin, MS, FNP-BCRead MoreReview Article
PD-1/PD-L1 Inhibitors for Non–Small Cell Lung Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management
Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP®Read MoreReview Article
Checkpoint Inhibitor Immunotherapy for Head and Neck Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management
Casey Fazer, PA-CRead MoreReview Article
Immune-Related Adverse Events From Immunotherapy: Incorporating Care Step Pathways to Improve Management Across Tumor Types
Laura S. Wood, RN, MSN, OCN®Read MoreAppendix
Care Step Pathway Tools for Immune-Related Adverse Event Assessment and Management
Read MoreEditorial
A Letter From the Guest Editors
Lisa A. Kottschade, APRN, MSN, CNP, and LeAnn B. Norris, PharmD, FCCP, BCPS, BCOPRead MoreEditorial
A Brighter Future for Patients With Melanoma
Lisa A. Kottschade, APRN, MSN, CNP, and LeAnn B. Norris, PharmD, FCCP, BCPS, BCOPRead MoreReview Article
Diagnosis, Evaluation, and Surgical Management of Melanoma
Brianna Hoffner, MSN, ANP-BC, AOCNP®, and Christan G. Bartsch, MSHS, PA-C, MPHRead MoreReview Article
Harnessing the Immune System in the Treatment of Melanoma
Suzanne McGettigan, MSN, CRNP, AOCN®Read MoreReview Article
BRAF/MEK Inhibition in Melanoma: An Update
Lisa A. Kottschade, APRN, MSN, CNP, and Kathleen M. Madden, RN, MSN, FNP-BC, AOCNP®, APHNRead MoreReview Article
Mutations Beyond BRAF V600
Mollie Reed, MSN, ACNP-BCRead MoreReview Article
Melanomas of Noncutaneous Origin: Diagnosis, Treatment, and Outcomes
Lisa A. Kottschade, APRN, MSN, CNPRead MoreReview Article
Supportive Care and Management of Treatment-Related Adverse Effects From Immune Checkpoint Inhibitors and Targeted Therapies in Melanoma
Krista M. Rubin, MS, FNP-BC, and Lisa A. Kottschade, APRN, MSN, CNPRead MoreReview Article
Drug-Drug Interactions in Melanoma
LeAnn B. Norris, PharmD, FCCP, BCPS, BCOPRead MoreAppendix
Appendix
Compiled by Lisa A. Kottschade, APRN, MSN, CNPRead MoreEditorial
A Letter From the Guest Editors
Sandra E. Kurtin, PhDc, ANP-C, AOCN®, and Ali McBride, PharmD, BCOPRead MoreContinuing Education
Chronic Lymphocytic Leukemia in 2018: What the Advanced Practitioner in Oncology Needs to Know
Sandra E. Kurtin, PhDc, ANP-C, AOCN®, and Ali McBride, PharmD, BCOPRead MoreReview Article
Scientific Advances in the Diagnosis and Risk Stratification of Chronic Lymphocytic Leukemia
Amy Goodrich, MSN, CRNP, and Nina Wagner-Johnston, MDRead MoreReview Article
Monoclonal Antibodies in Chronic Lymphocytic Leukemia
Lindsay Hladnik,(1) PharmD, BCOP, Kristan Augustin,(2) PharmD, BCOP, and Christopher Arp,(3) PharmDRead MoreReview Article
Small Molecules in Chronic Lymphocytic Leukemia: Novel Targets, New Challenges
Sandra E. Kurtin, PhDc, ANP-C, AOCN®, and Ali McBride, PharmD, BCOPRead MoreReview Article
Emerging Therapies in Chronic Lymphocytic Leukemia: Current Trials
Ashley E. Glode, PharmD, BCOP, and Hani M. Babiker, MDRead MoreReview Article
Risk-Adapted Treatment Strategies for Chronic Lymphocytic Leukemia
Lisa Nodzon, PhD, ARNP, AOCNP®, and Javier Pinilla-Ibarz, MD, PhDRead MoreReview Article
Supportive Care and Management of Treatment-Emergent Adverse Events in Chronic Lymphocytic Leukemia
Barbara Barnes Rogers, CRNP, MN, AOCN®, ANP-BC, and Nadia Khan, MDRead MoreReview Article
The Older Adult Living With Chronic Lymphocytic Leukemia: Implications for Oncology Providers, Patients, and Caregivers
Sandra E. Kurtin, PhDc, ANP-C, AOCN®Read MoreAppendix
Appendix
Compiled by Ali McBride, PharmD, BCOP, Andrew Garcia, PharmD, and Alyssa Hinchman, PharmDRead MoreEditorial
A Letter From The Guest Editor
Read MoreReview Article
The Role of the Advanced Practitioner in Maintaining Adherence in Patients on Oral Oncolytics
Kimberly M. Hicks,(1) PharmD, MHA, Diane Cope,(2) PhD, ARNP-BC, AOCNP®, John Novak,(3) CHA, PA-C, and Susan Scherer,(4) RN, BSN, OCNRead MoreEditorial
The Rise of Genetic Testing in Managing Patients With Ovarian Cancer
Patrick J. Kiel, PharmD, BCPS, BCOPRead MoreReview Article
The Emerging Role of Molecular Testing in Ovarian Cancer
Patrick J. Kiel,(1) PharmD, BCPS, BCOP, Courtney B. Cortez,(2) NP, Cynthia L. Hunter,(3) MS, LCGC, and Jeanne M. Schilder,(1) MDRead MoreEditorial
The Rise of Genetic Testing in Managing Patients With Non–Small Cell Lung Cancer
Patrick J. Kiel, PharmD, BCPS, BCOPRead MoreReview Article
The Emerging Role of Molecular Testing in Non–Small Cell Lung Cancer
Patrick J. Kiel,(1),(2) PharmD, BCPS, BCOP, Liang Cheng,(1) MD, Anna Livers-Ertel,(3) ANP-BC, MSN, OCN®, and Gregory Durm,(2) MDRead MoreEditorial
Introduction
Heather Hampel, MS, LGC, Guest EditorRead MoreReview Article
Lynch Syndrome and Immunotherapy
Heather Hampel, MS, LGC, and Brianna Hoffner, MSN, ANP-BC, AOCNP®Read MoreReview Article
BRCA-Related Ovarian Cancers and the Role of PARP Inhibitor Therapy
Leigha Senter, MS, LGC, and Paula Anastasia, RN, MN, AOCN®Read MoreContinuing Education
CAR T-Cell Therapy: An Approach Whose Time Has Come
Read MoreContinuing Education
The Latest Advances in CAR T-Cell Therapy for Refractory and Relapsed Lymphomas and Leukemias
Marco L. Davila, MD, PhDRead MoreEditorial
Letter From the Guest Editors
Read MoreEditorial
Take a Deep Breath: More Treatment Options for Non–Small Cell Lung Cancer
Lisa Cordes, PharmD, BCACP, BCOP, and Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BCRead MoreReview Article
Diagnosis of Lung Cancer
Marianne Davies, DNP, MSN, CNS, ACNP, AOCNP®, and Helen Shih, MSN, MPHRead MoreReview Article
Fundamentals of Lung Cancer Staging
Marianne Davies, DNP, MSN, CNS, ACNP, AOCNP®Read MoreReview Article
Predictive and Prognostic Biomarkers and Related Therapies in Non–Small Cell Lung Cancer
Samantha Schmidt, PharmD, and Grashma Vadakkel, PharmD(c)Read MoreReview Article
Supportive Care and Management of Treatment-Emergent Adverse Events With Targeted Therapy in Non–Small Cell Lung Cancer
Clell Hasenbank, PharmDRead MoreReview Article
Emerging Biomarkers in Non–Small Cell Lung Cancer
Melinda Oliver, BA, BSN, RN, MPAPRead MoreReview Article
Immunotherapy Mechanisms of Action in Non–Small Cell Lung Cancer
Beth Eaby-Sandy, MSN, CRNP, OCN®Read MoreReview Article
Unleashing the Immune System With Checkpoint Inhibitors in Non–Small Cell Lung Cancer: Clinical Review of Adverse Events
Sandra Cuellar, PharmD, BCOPRead MoreReview Article
Emerging Therapies in Non–Small Cell Lung Cancer: Clinical Trials With Novel Agents
Karen Oishi, MSN, APRN, AGPCNP-BC, OCN®Read MoreTools and Technology
Resources for Patients With Non–Small Cell Lung Cancer and Their Caregivers and Providers
Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BCRead MoreAppendix
Appendix
Lisa Cordes, PharmD, BCACP, BCOPRead MoreEditorial
Priming the Pump Task Force
Read MoreContinuing Education
Continuing Education Information
Read MoreContinuing Education
Meet the Team
Read MoreContinuing Education
Managing the Care of Patients With HER2-Positive Breast Cancer: A Collaborative Practice Model
Angela DeMichele, MD, MSCE; Jennie Greco Lattimer, MSN, BSN, CRNP; and Rachel F.Read MoreAppendix
Appendix
Managing the Care of Patients With HER2-Positive Breast Cancer: A Collaborative Practice ModelRead MoreContinuing Education
Continuing Education Information
Read MoreEditorial
The Future is Bright
Sandra Kurtin, RN, MSN, AOCN®, ANP-CRead MoreEditorial
The Continuum of Care in Multiple Myeloma Redefined: Challenges and Opportunities
Sandra Kurtin, RN, MSN, AOCN®, ANP-C, Guest EditorRead MoreReview Article
Sequencing of Treatment and Integration of Clinical Trials
Beth Faiman,(1) PhD, MSN, APRN-BC, AOCN®, Charise Gleason,(2) MSN, NP-BC, AOCNP®, Kathleen Colson,(3) RN, BSN, BS, Ann McNeill,(4) RN, MSN, APN, and Donna Catamero,(5) ANP-BC, OCN®, CCRC, on behalf of the International Myeloma Foundation Nurse Leadership BoardRead MoreReview Article
Palliative Care in Multiple Myeloma
Tiffany Richards,(1) MS, ANP, AOCNP®, and Kevin Brigle,(2) PhD, NP, on behalf of the International Myeloma Foundation Nurse Leadership BoardRead MorePrescriber's Corner
New Agents in the Treatment of Multiple Myeloma
Beth Faiman,(1) PhD, MSN, APRN-BC, AOCN®, Ali McBride,(2) PharmD, MS, BCPS, BCOP, Hollie Devine,(3) MSN, ANP-BC, Charise Gleason,(4) MSN, NP-BC, AOCNP®, and Sandra Kurtin,(5) RN, MSN, AOCN®, ANP-C, on behalf of the International Myeloma Foundation Nurse Leadership BoardRead MorePrescriber's Corner
Monoclonal Antibodies in the Treatment of Multiple Myeloma
Charise Gleason,(1) MSN, NP-BC, AOCNP®, Hollie Devine,(2) MSN, ANP-BC, Beth Faiman,(3) PhD, MSN, APRN-BC, AOCN®, Deborah Doss,(4) RN, OCN®, and Sandra Kurtin,(5) RN, MSN, AOCN®, ANP-C, on behalf of the International Myeloma Foundation Nurse Leadership BoardRead MoreGrand Rounds
Updates in the Diagnosis and Monitoring of Multiple Myeloma
Sandra Kurtin,(1) RN, MSN, AOCN®, ANP-C, Page Bertolotti,(2) RN, BSN, OCN®, Kevin Brigle,(3) PhD, NP, and Daniel Verina,(4) BS, BSN, MSN, ACNP-BC, on behalf of the International Myeloma Foundation Nurse Leadership BoardRead MorePractice Matters
Adherence, Persistence, and Treatment Fatigue in Multiple Myeloma
Sandra Kurtin,(1) RN, MSN, AOCN®, ANP-C, Kathleen Colson,(2) RN, BSN, BS, Joseph Tariman,(3) PhD, ANP-BC, Beth Faiman,(4) PhD, MSN, APRN-BC, AOCN®, and Elizabeth Finley-Oliver,(5) RN, BSN, OCN, on behalf of the International Myeloma Foundation Nurse Leadership BoardRead MoreTools and Technology
Resources for Patients and Caregivers With Multiple Myeloma and Their Providers
Kevin Brigle, PhD, NP, on behalf of The International Myeloma Foundation Nurse Leadership BoardRead MoreAppendix
Multiple Myeloma Treatment Options for Newly Diagnosed, Relapsed, and Refractory Disease
Kimberly Noonan,(1) RN, ANP, AOCN®, Teresa S. Miceli,(2) RN, BSN, OCN®, Patricia Mangan,(3) RN, MSN, APRN-BC, and Sandra Rome,(4) RN, MN, AOCN®, CNS, on behalf of the International Myeloma Foundation Nurse Leadership BoardRead MoreContinuing Education
Continuing Education Information
Read MoreMeeting Report
Meet The Panel
Read MoreMeeting Abstract
Methotrexate and Fluorouracil Toxicities: What Advanced Practitioners in Oncology Need to Know
Read MoreMeeting Abstract
Case Studies: Collaborative Practice In Action
Read MoreMeeting Abstract
Questions Answered About Glucarpidase
Read MoreMeeting Abstract
Questions Answered About Uridine Triacetate
Read MoreContinuing Education
Continuing Education Information
Read MoreEditorial
Collaborative Practice Enhances Supportive Care in Cancer: Chemotherapy-Induced Nausea and Vomiting
Rita Wickham, PhD, RN, AOCN® Sally Barbour, PharmD, BCOP, CPP Teresa Scardino, RPA-C, MPASRead MoreReview Article
Risks for Chemotherapy-Induced Nausea and Vomiting: Capturing Relevant Data
Teresa Scardino, RPA-C, MPASRead MoreReview Article
Actualizing Standards of Care for Chemotherapy-Induced Nausea and Vomiting
Sally Barbour, PharmD, BCOP, CPPRead MoreReview Article
Managing Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future
Rita Wickham, PhD, RN, AOCN®Read MoreGrand Rounds
Managing Chemotherapy-Induced Nausea and Vomiting: An Adaptable, Collaborative Approach for a Patient With Colon Cancer
Rita Wickham, PhD, RN, AOCN®, Sally Barbour, PharmD, BCOP, CPP, and Teresa Scardino, RPA-C, MPASRead MoreReview Article
Relapsed or Relapsed/Refractory Multiple Myeloma
Sandra E. Kurtin, RN, MS, AOCN®, ANP-CRead MorePrescriber's Corner
Carfilzomib
J. Michael Vozniak, PharmD, BCOPRead MoreReview Article
The Side Effect Profile of Carfilzomib: From Clinical Trials to Clinical Practice
Laura McBride, RN, BSN, OCN®, CCRP, and Christine O. Samuel, RN, BSN, OCN®, CCRPRead MoreGrand Rounds
Treatment of Patients With Multiple Myeloma: A Relapsed and Refractory Case Study
Sandra E. Kurtin, RN, MS, AOCN®, ANP-CRead MoreReview Article
Treatment With Carfilzomib: A Promising Future for Multiple Myeloma
Donna Catamero, ANP-BC, OCN®, CCRC, and Charise Gleason, MSN, ANP, AOCNP®Read MoreContinuing Education
Continuing Education Information
Read MoreReview Article
Monitoring, Treatment Resistance, and Treatment Failure in CML: Breaking Barriers to Improved Outcomes
Jorge Eduardo Cortes, MD(1). John M. Goldman, DM, FRCP, FRCPath, FMedSci(2), and Timothy P. Hughes, MD, MBBS(3); Faculty Perspectives by Patricia S. Ault, RN, FNP(1), and Mary Beth Rios, CCRP, RN(1)Read MoreContinuing Education
Continuing Education Information
Read MoreEditorial
Managing Hematologic Malignancies: The Balancing Act
Sandra Kurtin, RN, MS, AOCN®, ANP-CRead MoreReview Article
Current Approaches to the Diagnosis and Management of Myelodysplastic Syndromes
Sandra Kurtin, RN, MS, AOCN®, ANP-CRead MoreReview Article
Risk Stratification and Management of Acute Myeloid Leukemia
Jean A. Ridgeway, MSN, APN, NP-C, AOCN®Read MoreReview Article
Update on the Management of Follicular Lymphomas
Amy Goodrich, MSN, CRNPRead MoreReview Article
Management of Multiple Myeloma and Serious Side Effects
Elizabeth Bilotti, MSN, RN, APN, OCN®Read MoreContinuing Education
Continuing Education Information
Read MoreReview Article
Oral Mucositis: Addressing the Causes, Challenges, and Clinical Management
Carrie F. Daly, MS, RN, AOCN®, and Annette M. Quinn, MSN, RNRead More